HFpEF Banner

Are you ready to join the HFpEF Drug Discovery & Development movement?

Taking place this January in Boston, the HFpEF Drug Discovery & Development Summit 2022 is the first and only devoted meeting uniting large pharma, biotech, and pioneering academics under the mutual and ambitious objective of accelerating the practical discovery, translation, and clinical development of safe, effective and deliverable therapies to treat HFpEF, an extremely common heart failure with a huge unmet medical need.

Join 80+ experts at this ground-breaking forum with the likes of AstraZeneca, Eli Lilly, Bayer, Amgen, Novartis, and many more sharing state-of-the-art insights and expertise in heart failure. Covering topics including specific and applied drug development hurdles with inadequate successful treatments, such as the translational challenges between phases of pre-clinical and clinical trials, this is a conversation not to miss.

Attending this summit will equip you with the information and partnerships to succeed and translate drug candidates into human clinical trials, whilst optimizing your clinical development process itself to evade further clinical failures.

Why the Industry is Excited to Attend:

HW2100807 HFpEF Drug Discovery & amp Development image logo

“The opportunity to meet and discuss a topic as complex as HFpEF in a dedicated meeting with ample time and with a common goal does not come often and is highly appreciated”

Ola Vedin, Global Medical Director Heart Failure, Boehringer Ingelheim

HW2100807 HFpEF Drug Discovery & amp Development image logo

“I’m looking forward to exchanging with experts tackling the same challenges in the field, share learnings, and make new connections to the benefit of all stakeholders”

Richard Nkulikiyinka, Vice President, Head of Therapeutic Area Cardiology & Nephrology, Bayer

HW2100807 HFpEF Drug Discovery & amp Development image logo

“I’m excited to sharing our experience with fellow researchers in terms of contemporary knowledge regarding disease drivers of HFpEF as well clinical diagnostic approaches to quantify microvascular dysfunction”

Li-Min Gan, Vice President and Head of Early Clinical Development, AstraZeneca

Your HFpEF Trailblazing Speakers:

Proud to Partner With:

CCS_Logo_HFpEF
AnaBios_logo_rgb_color (002)
Logo Physiogenex (002)
om1_logo_HFpEF

The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*. For further information around Health and Safety onsite, please visit our FAQ here.

 

*Please note, this is subject to change at any time without prior notice.